Sanara MedTech (NASDAQ:SMTI) PT Lowered to $44.00

Sanara MedTech (NASDAQ:SMTI) had its price objective cut by equities researchers at Cantor Fitzgerald from $49.00 to $44.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Cantor Fitzgerald’s price target would indicate a potential upside of 18.92% from the company’s current price.

Sanara MedTech Price Performance

SMTI opened at $37.00 on Wednesday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.09 and a current ratio of 1.38. Sanara MedTech has a 1-year low of $26.06 and a 1-year high of $50.18. The company has a 50-day moving average of $37.01 and a 200-day moving average of $34.72. The company has a market capitalization of $318.94 million, a P/E ratio of -71.73 and a beta of 1.59.

Institutional Investors Weigh In On Sanara MedTech

Institutional investors have recently modified their holdings of the business. UBS Group AG grew its position in shares of Sanara MedTech by 138.8% during the 1st quarter. UBS Group AG now owns 609 shares of the company’s stock valued at $25,000 after buying an additional 354 shares during the last quarter. Tower Research Capital LLC TRC grew its position in shares of Sanara MedTech by 363.4% during the 3rd quarter. Tower Research Capital LLC TRC now owns 797 shares of the company’s stock valued at $25,000 after buying an additional 625 shares during the last quarter. Barclays PLC bought a new stake in shares of Sanara MedTech during the 2nd quarter valued at about $30,000. Gladius Capital Management LP bought a new stake in shares of Sanara MedTech during the 4th quarter valued at about $45,000. Finally, California State Teachers Retirement System bought a new stake in shares of Sanara MedTech during the 2nd quarter valued at about $51,000. Institutional investors own 8.10% of the company’s stock.

About Sanara MedTech

Sanara MedTech Inc develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It also offers CellerateRX Surgical Activated Collagen powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako¯s Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako¯s Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako¯s Antimicrobial Skin and Wound Irrigation Solution.